Ocular hypertension Glaucoma

Disc hemorrhages are an important prognostic indicator in the assessment and management of glaucoma and ocular hypertension. Glaucoma patients who develop disc hemorrhages are more likely to develop optic nerve... 

Granuloma gluteal infantum Tinea incognito Scabies incognito Ophthalmic Ocular hypertension Glaucoma Cataracts Pharmacologic... 

Brimonidine tartrate is an alph -adrenergic receptor agonist used to lower IOP in patients with open-angle glaucoma or ocular hypertension. This drug acts to reduce aqueous humor production and increase the outflow of aqueous humor. 

Patients with ocular hypertension or primary open-angle glaucoma typically have a slow, insidious loss of vision. This is contrasted by the course of acute primary angle-closure glaucoma which can lead to rapid vision loss that develops over hours to days. 

Maoris N. Glucocorticoid use and risks of ocular hypertension and glaucoma. 

TREATMENT OF OCULAR HYPERTENSION AND OPEN-ANGLE GLAUCOMA... 

T reatment is indicated for ocular hypertension if the patient has a significant risk factor such as IOP greater than 25 mm Hg, vertical cup-disk ratio greater than 0.5, or central corneal thickness less than 555 micrometers. Additional risk factors to be considered include family history of glaucoma, black race, severe myopia, and presence of only one eye. 

Intraocular pressure (lOP) To lower lOP in patients with open-angle glaucoma or ocular hypertension. 

Elevated intraocular pressure f/OPJ Treatment of elevated lOP in patients with ocular hypertension or open-angle glaucoma. 

Elevated intraocular pressure (lOP) For reduction of elevated lOP in patients with open-angle glaucoma and ocular hypertension who are intolerant of other lOP-lowering medications or insufficiently responsive to another lOP-lowering medication. 

Blockers can reduce intraocular pressure in glaucoma and ocular hypertension. The mechanism is believed to be related to a decreased production of aqueous humor. 

Blockers can be used topically to reduce intraocular pressure in patients with chronic open-angle glaucoma and ocular hypertension. The mechanism by which ocular pressure is reduced appears to depend on decreased production of aqueous humor. Timolol has a somewhat greater ocular hypotensive effect than do the available cholinomimetic or adrenomimetic drugs. The 3-blockers also are beneficial in the treatment of acute angle-closure glaucoma. 

Travoprost is an ester that acts as a pro-drug of a fluoro analogue of prostaglandin PGF200 which is a full agonist of the prostaglandin F (FP) receptor. It is marketed for the topical treatment of intra-ocular hypertension and glaucoma (Fig. 72) [167]. 

P.A. Netland, T. Landry, E.K. Sullilvan, R. Andrew, L. Silver, A. Weiner, S. Mallick, J. Dickerson, M.V. Bergamini, S.M. Robertson, A.A. Davis, Travoprost compared with latanoprost and timolol in patients with open-angle glaucoma or ocular hypertension. Am. J. Ophthalmol. 132 (2001) 472. 

Chronic open-angle glaucoma and ocular hypertension Ophthalmic (solution) 1 drop... 

Glaucoma, ocular hypertension Ophthalmic 1 drop in affected eye(s) once daily, in the evening. 

The ophthalmic form may cause glaucoma, ocular hypertension, and cataracts. 

Ocular hypertension and open-angle glaucoma are well-known adverse effects of ophthalmic administration of glucocorticoids (SEDA-17, 449). 

Glaucoma and ocular hypertension have been reported after dermal application of glucocorticoids for facial atopic eczema (SEDA-19,376) (64), and after treatment with beclomethasone by nasal spray and inhalation (SEDA-20, 373 65). 

Glucocorticoid creams applied topically to the skin are routinely used in the treatment of many skin disorders, and their use on the face in severe atopic eczema is relatively common. Three patients developed advanced glaucoma while using topical facial glucocorticoids. Two other patients developed ocular hypertension secondary to topical facial glucocorticoids (430). 

Garbe E, LeLorier J, Boivin JF, Suissa S. Risk of ocular hypertension or open-angle glaucoma in elderly patients on oral glucocorticoids. Lancet 1997 350(9083) 979-82. 

---